Peptide
Contacts
Vendors
Peptides
Experts
Research
Learn
Community
News
Tools
Search...
⌘K
Log in
Sign Up
Open menu
REGULATORY
RFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026
UPDATE
Semaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025
REGULATORY
BPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pending
FDA
FDA advisory committee meetings scheduled: late July 2026
RESEARCH
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]
RESEARCH
Metabolic Effects of Angiotensin-(1-7) [NCT02646475]
RESEARCH
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]
RESEARCH
Multi-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]
RESEARCH
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]
RESEARCH
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]
RESEARCH
Tirzepatide in the Treatment of Endometrial Cancer [NCT07605247]
RESEARCH
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]
RESEARCH
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]
NEWS
Oorja, run by Acceleron veterans, launches to make new fibrosis drugs
REGULATORY
RFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026
UPDATE
Semaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025
REGULATORY
BPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pending
FDA
FDA advisory committee meetings scheduled: late July 2026
RESEARCH
A Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]
RESEARCH
Metabolic Effects of Angiotensin-(1-7) [NCT02646475]
RESEARCH
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]
RESEARCH
Multi-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]
RESEARCH
A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]
RESEARCH
Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]
RESEARCH
Tirzepatide in the Treatment of Endometrial Cancer [NCT07605247]
RESEARCH
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]
RESEARCH
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]
NEWS
Oorja, run by Acceleron veterans, launches to make new fibrosis drugs
For research purposes only.
Full disclaimer →
All Contacts
JA
Clinician
Joseph Antoun
Longevity / Fasting Medicine
W